会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明公开
    • 엔,엔-디이소프로필-4-[7-(4-아미노페녹시)헵톡시]-3-메톡시벤즈아미드의 골다공증 예방 및 치료제로서의 용도
    • 使用N,N-二异丙基-4-(7-(4-氨基苯氧基)羟基)-3-甲氧基苯甲酰胺作为预防和/或治疗剂用于卵泡发育
    • KR1020030008653A
    • 2003-01-29
    • KR1020010043489
    • 2001-07-19
    • 동화약품주식회사서홍석
    • 이진수김판수황연하유제만정용호서홍석김도희박용엽
    • A61K31/166
    • PURPOSE: Provided is N,N-diisopropyl-4-(7-(4-aminophenoxy)heptoxy)-3-methoxybenzamide(DW1259) which has leukotriene-B4 receptor antagonistic action and has excellent effects on inhibition of bone absorption by effectively inhibiting the function of osteoclast cells. CONSTITUTION: The agent for prophylaxis and treatment of osteoporosis contains an effective amount of N,N-diisopropyl-4-(7-(4-aminophenoxy)heptoxy)-3-methoxybenzamide of formula(1). The compound has an excellent inhibition effect on a differentiation, formation, fusion process and bone absorption function of osteoclast cells, is excellent in an inhibition function of osteoclast cells as compared to any compound such as DW1231, DW1234, DW1166, DW1235 having structural similarity as well as HS-1141 and CGS-25019C and has increased efficacy in increasing the activity of osteoblast cells.
    • 目的:提供具有白三烯-B4受体拮抗作用的N,N-二异丙基-4-(7-(4-氨基苯氧基)庚氧基)-3-甲氧基苯甲酰胺(DW1259),并且通过有效抑制 破骨细胞功能。 构成:用于预防和治疗骨质疏松症的药物含有有效量的式(1)的N,N-二异丙基-4-(7-(4-氨基苯氧基)乙氧基)-3-甲氧基苯甲酰胺。 该化合物对破骨细胞的分化,形成,融合过程和骨吸收功能具有优异的抑制作用,与​​具有结构相似性的任何化合物如DW1231,DW1234,DW1166,DW1235相比,破骨细胞的抑制功能优异 以及HS-1141和CGS-25019C,并且增加了成骨细胞活性的功效。
    • 10. 发明公开
    • 신규의 메톡시-1,3,5-트리아진 유도체 및 그를 포함하는약학적 조성물
    • 甲氧基-1,3,5-三嗪衍生物和含有它们的药物组合物
    • KR1020020076920A
    • 2002-10-11
    • KR1020010017143
    • 2001-03-31
    • 동화약품주식회사
    • 정용호이치우양왕용이학동박휘정장윤영이진수
    • C07D413/14
    • C07D403/14C07D401/14C07D403/12C07D413/14
    • PURPOSE: Provided are a methoxy-1,3,5-triazine derivative which inhibit the growth of Hepatitis C virus(HCV) and a pharmaceutical composition containing the same, therefore it can be useful for the prevention and treatment of hepatitis type B and hepatitis type C. CONSTITUTION: The methoxy-1,3,5-triazine derivative is represented by formula(1) and its pharmaceutically acceptable salt are provided. In the formula(1), R1 is H or C1-C8 alkyl; R2 is H, hydroxy, C1-C4 linear or branched chain alkyl, C1-C3 linear or branched chain alkoxy, C1-C3 hydroxyalkyl, C2-C6 dialkylamino, C3-C6 cycloalkyl, lactam, saturated or unsaturated 5 or 6 atom hetero ring compound optionally substituted with C1-C3 linear or branched chain alkyl substituted or unsubstituted, and containing one or two hetero atom selected from N, O and S; or bicyclo compound containing one or two hetero atom selected from N, O and S; n is an integer of 0 to 4; and R3 is 5-indazolyl or 6-indazolyl. The method for producing the methoxy-1,3,5-triazine derivative comprises the steps of: reacting 2,4-dichloro-6-methoxy-1,3,5-triazine of formula(4) with 5-aminoindazole or 6-aminoindazole of formula(5) in the presence of base to prepare aminoindazole substituted 2-chloro-6-methoxy-1,3,5-triazine derivative of formula(6); and reacting the compound of formula(6) with amine compound of formula(7) in the presence of amine to prepare methoxy-1,3,5-triazine derivative of formula(1).
    • 目的:提供抑制丙型肝炎病毒(HCV)生长的甲氧基-1,3,5-三嗪衍生物和含有该丙氨酸病毒(HCV)的药物组合物,因此可用于预防和治疗乙型肝炎和肝炎 C型。构成:提供甲氧基-1,3,5-三嗪衍生物由式(1)表示,并提供其药学上可接受的盐。 在式(1)中,R 1是H或C 1 -C 8烷基; R2是H,羟基,C1-C4直链或支链烷基,C1-C3直链或支链烷氧基,C1-C3羟基烷基,C2-C6二烷基氨基,C3-C6环烷基,内酰胺,饱和或不饱和的5或6原子杂环 任选被取代或未取代的C 1 -C 3直链或支链烷基取代的,含有一个或两个选自N,O和S的杂原子的化合物; 或含有一个或两个选自N,O和S的杂原子的双环化合物; n为0〜4的整数。 并且R 3是5-吲唑基或6-吲唑基。 制备甲氧基-1,3,5-三嗪衍生物的方法包括以下步骤:使式(4)的2,4-二氯-6-甲氧基-1,3,5-三嗪与5-氨基吲唑或6- 式(5)的氨基吲唑在碱的存在下反应,制备式(6)的氨基吲唑取代的2-氯-6-甲氧基-1,3,5-三嗪衍生物; 并在胺的存在下使式(6)的化合物与式(7)的胺化合物反应,制得式(1)的甲氧基-1,3,5-三嗪衍生物。